Anyone who's ever decorated a home—whether a studio apartment that barely spans 500 square feet or a multi-bedroom, single-family house—knows that good furniture doesn't come cheap. We use the term "good" loosely because, well, what does that even mean? In this case, it refers to the quality of construction, which, more often than not, informs longevity. Though there are exceptions, the general rule of thumb is as follows: The better the materials and manufacturing processes are, the longer the furniture in question will last. You may also be trying to determine how best to spend your decorating budget in accordance with your household's priorities—does it make more sense to splurge on a well-built sofa that's going to get a lot of daily use or a solid wood cabinet for a guest bedroom that could last generations? Luckily, we have a great starting point for you.We asked Dan Campbell, president of BenchMade Modern, for his expertise on the subject. His paramount piece of advice for anyone willing to spend a pretty penny on luxury furniture is this: "Look for furniture that's handcrafted in the United States, as this ensures high-quality materials as well as craftsmanship," he says. "When something is custom-made or made-to-order, this creates the best option as the piece is crafted based on the features the end user really needs."Ahead, he shares what furniture pieces tend to last longer and what's worth the investment. We'd also like to preface that all of our life expectancy timelines are generalizations and presume that these are investment-worthy pieces that are carefully maintained and cared for—all the more reason to buy the best quality you can!Related StoriesSofasDesign: Sarah Vaile Design, Photo: Lesley UnruhSofas are tricky because there are a lot of elements that go into their creation, namely the frame, cushions, and upholstery. Even if they're made of the best-quality materials, longevity is not a guarantee. Campbell asks, "Who is using it, and where does it live? Are there kids and pets? Is it in a high-traffic area like a media room or more of a display piece in a formal living room?" Once you have that key information, you can choose the right piece for your specific space that, Campbell says, will last for many, many years. The part of most sofas that'll usually start deteriorating first is the cushioning. With this in mind, you can shop for models that prioritize durability. "A combination of foam and fiber will have the most resiliency, and that 'tailored' (as opposed to 'sink-in') look for the longest period," he says. "But many people have comfort as their primary goal over longevity. A very dense foam will hold up the longest, but the denser the foam is, the less comfortable the sofa can be. It is also an aesthetic question, as a down or down alternative fill is going to give you a more casual look that will require some fluffing to maintain its look, but is still super durable." The best way to maintain the health of your cushions is to flip and fluff them every few months. "Rotate them like you would your car tires. This will give all of the cushions more equal wear over time, so the sofa looks great throughout the years," Campbell advises.Life expectancy of a sofa: 10 yearsRelated StoryBed FramesDesign: Sarah Richardson Design and Murakami Design, Photo: Valerie WilcoxWhen buying a bed frame, you basically have two options: wood or upholstered. You really can't go wrong with either, so invest in the one you prefer in terms of comfort and aesthetics. That said, wood will last a long time (pretty much forever if it's well-made) without you having to put too much effort into maintaining it. If you are dead-set on an upholstered bed frame, just make sure to choose your fabric wisely. "If you select a white linen headboard, it's not going to look great in the years to come," Campbell explains. "Instead, consider a white linen-like performance fabric that you can easily clean." Life expectancy of a wooden bed frame: ImmortalUpholstered bed frame: 20-30 yearsRelated StoryDining ChairsDesign: The Galeana Group, Photo: Matthew NiemannSimilar to dressers (which we'll get to in a moment), high-quality dining chairs are more about construction than material because, well, they get a lot of action. "Regardless of the type of chair you get (all wood, an upholstered seat, or fully upholstered), these pieces take the most abuse, as they're constantly being pulled in and out, leaned against, sliding…the legs need to be able to handle the stress," Campbell admits. "You will see the failure of dining chairs from a low-end manufacturer very quickly." If you can only splurge on one piece of furniture, let it be your dining chairs. The easiest to care for is an all-wood option, but if you want an upholstered set, make sure it's performance-grade fabric.Life expectancy of all-wood dining chairs: ImmortalDining chairs with upholstered seats: 10-20 yearsAll-upholstered dining chairs: 10-15 yearsRelated StoryDining TablesDesign: Liz Caan & Co., Photo: Eric RothWhat most often causes a dining table to deteriorate over time is its lack of stability, which, of course, goes back to what Campbell has been saying this whole time: It's all about the materials used and craftsmanship. Those two elements will make for a stable and durable table that will last pretty much forever if they're properly cared for. When do you know if it's time to put some TLC into your dining table? "Make sure there aren't any loose components," Campbell says. "The table's legs shouldn't wobble if weight is placed on any side. The base of the table or the legs should have a secure fit to the tabletop."You may be thinking a glass-top dining table is probably inferior (in terms of lifespan) to solid wood options, but Campbell argues that if a dining table boasts a glass top, it's designed to be used and loved. "They're very easy to clean and also durable," he notes. "If your dining table has a glass top, it's typically made to withstand regular usage. Should disaster strike, there are options to replace it if the original breaks." If you don't feel like dealing with that possibility, go with wood. However, wood is not indestructible either. "Solid wood ages really well, but it can crack and splinter over time. So, if you're OK with the live-edge or more rustic look, solid wood is a fantastic option," Campbell explains. "Veneering on medium-density fiberboard is a stable, long-term option, too. Both can be refinished: Solid wood can be refinished many times and veneered less often, depending on the thickness of the veneer."Life expectancy of a glass-top dining table: VariableSolid wood dining table: ImmortalRelated StoryDressersDesign: Gleason & Gleason, Photo: David TsayAs you may have guessed, the dressers that tend to last the longest are made of solid wood. "High-end dressers that withstand the test of time are typically crafted from solid wood— more specifically, stronger woods that wear well, such as cherry, oak, and maple," Campbell says. "However, because solid wood can crack, splinter, swell, or shrink over time, a veneer can create a long-lasting piece." Life expectancy of a solid wood dresser: ImmortalFollow House Beautiful on Instagram and TikTok.

This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of technology. This baby boy was treated with the first personalized gene-editing drug Doctors say they constructed a bespoke gene-editing treatment in less than seven months and used it to treat a baby with a deadly metabolic condition. The rapid-fire attempt to rewrite the child’s DNA marks the first time gene editing has been tailored to treat a single individual. The baby who was treated, Kyle “KJ” Muldoon Jr., suffers from a rare metabolic condition caused by a particularly unusual gene misspelling. Researchers say their attempt to correct the error demonstrates the high level of precision new types of gene editors offer.The project also highlights what some experts are calling a growing crisis in gene-editing technology. That’s because even though the technology could cure thousands of genetic conditions, most are so rare that companies could never recoup the costs of developing a treatment for them. Read the full story.—Antonio Regalado Access to experimental medical treatments is expanding across the US —Jessica Hamzelou A couple of weeks ago I was in Washington, DC, for a gathering of scientists, policymakers, and longevity enthusiasts. They had come together to discuss ways to speed along the development of drugs and other treatments that might extend the human lifespan. One approach that came up was to simply make experimental drugs more easily accessible. Now, the state of Montana has passed a new bill that sets out exactly how clinics can sell experimental, unproven treatments in the state to anyone who wants them. The passing of the bill could make Montana something of a US hub for experimental treatments. But it represents a wider trend: the creep of Right to Try across the US. And a potentially dangerous departure from evidence-based medicine. Read the full story. This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here. Take a new look at AI’s energy use Big Tech's appetite for energy is growing rapidly as adoption of AI accelerates. But just how much energy does even a single AI query use? And what does it mean for the climate? Join editor in chief Mat Honan, senior climate reporter Casey Crownhart, and AI reporter James O'Donnell at 1.30pm ET on Wednesday May 21 for a subscriber-only Roundtables conversation exploring AI's energy demands now and in the future. Register here. The must-reads I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology. 1 xAI has blamed Grok’s white genocide fixation on an ‘unauthorized modification’ Made by an unnamed employee at 3.15am. (TechCrunch)+ The topic is one the far-right comes back to again and again. (The Atlantic $)+ Memphis residents are struggling to live alongside xAI’s supercomputer. (CNBC) 2 Meta has delayed the launch of its next flagship AI model Its engineers are struggling to improve its Behemoth LLM enough. (WSJ $)3 Elon Musk is tapping up friends and allies for federal jobs It’s creating an unprecedented web of potential conflicts of interests. (WSJ $)+ Musk is posting on X less than he used to. (Semafor)4 The US is slashing funding for scientific research Such projects produced GPS, LASIK eye surgery, and CAPTCHAs. (NYT $)+ US tech visa applicants are under seriously heavy scrutiny. (Wired $)+ The foundations of America’s prosperity are being dismantled. (MIT Technology Review)They’re focusing on improving chatbots’ memory—but critics are worried. (5 Big Tech wants its AI agents to remember everything about you 🧠FT $)+ AI agents can spontaneously develop human-like behavior. (The Guardian)+ Generative AI can turn your most precious memories into photos that never existed. (MIT Technology Review)6 People keep making anti-DEI modifications for The Sims 4 And the gamemaker EA’s attempts to stamp them out aren’t working. (Wired $) 7 This chatbot promises to help you get over your ex  Closure creates an AI version of ex-partners for users to vent their frustrations at. (404 Media)+ The AI relationship revolution is already here. (MIT Technology Review)8 How this AI song became a viral megahit in JapanYAJU&U is completely inescapable, and totally nonsensical. (Pitchfork) + AI is coming for music, too. (MIT Technology Review) 9 Your future overseas trip could be by zeppelin If these startups get their way. (WP $)+ Welcome to the big blimp boom. (MIT Technology Review)10 Are you a ‘dry texter’? 💬 It’s a conflict-averse teen’s worst nightmare. (Vox) Quote of the day “It’s OK to be Chinese overseas.” —Chris Pereira, the CEO of iMpact, a communications firm advising Chinese companies expanding abroad, tells Rest of World that DeepSeek has given Chinese startups the confidence not to hide their origins. One more thingWe’ve never understood how hunger works. That might be about to change. When you’re starving, hunger is like a demon. It awakens the most ancient and primitive parts of the brain, then commandeers other neural machinery to do its bidding until it gets what it wants. Although scientists have had some success in stimulating hunger in mice, we still don’t really understand how the impulse to eat works. Now, some experts are following known parts of the neural hunger circuits into uncharted parts of the brain to try and find out. Their work could shed new light on the factors that have caused the number of overweight adults worldwide to skyrocket in recent years. And it could also help solve the mysteries around how and why a new class of weight-loss drugs seems to work so well. Read the full story. —Adam Piore We can still have nice things A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line or skeet 'em at me.)+ Who knew—Harvard Law School’s Magna Carta may be the real deal after all.+ Early relatives of reptiles might have walked the Earth much earlier than we realised.+ New York University’s MFA Students are a talented bunch.+ The Raines sandwich sounds unspeakably awful 🥪

This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of technology. This baby boy was treated with the first personalized gene-editing drug Doctors say they constructed a bespoke gene-editing treatment in less than seven months and used it to treat a baby with a deadly metabolic condition. The rapid-fire attempt to rewrite the child’s DNA marks the first time gene editing has been tailored to treat a single individual. The baby who was treated, Kyle “KJ” Muldoon Jr., suffers from a rare metabolic condition caused by a particularly unusual gene misspelling. Researchers say their attempt to correct the error demonstrates the high level of precision new types of gene editors offer.The project also highlights what some experts are calling a growing crisis in gene-editing technology. That’s because even though the technology could cure thousands of genetic conditions, most are so rare that companies could never recoup the costs of developing a treatment for them. Read the full story.—Antonio Regalado Access to experimental medical treatments is expanding across the US —Jessica Hamzelou A couple of weeks ago I was in Washington, DC, for a gathering of scientists, policymakers, and longevity enthusiasts. They had come together to discuss ways to speed along the development of drugs and other treatments that might extend the human lifespan. One approach that came up was to simply make experimental drugs more easily accessible. Now, the state of Montana has passed a new bill that sets out exactly how clinics can sell experimental, unproven treatments in the state to anyone who wants them. The passing of the bill could make Montana something of a US hub for experimental treatments. But it represents a wider trend: the creep of Right to Try across the US. And a potentially dangerous departure from evidence-based medicine. Read the full story. This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here. Take a new look at AI’s energy use Big Tech's appetite for energy is growing rapidly as adoption of AI accelerates. But just how much energy does even a single AI query use? And what does it mean for the climate? Join editor in chief Mat Honan, senior climate reporter Casey Crownhart, and AI reporter James O'Donnell at 1.30pm ET on Wednesday May 21 for a subscriber-only Roundtables conversation exploring AI's energy demands now and in the future. Register here. The must-reads I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology. 1 xAI has blamed Grok’s white genocide fixation on an ‘unauthorized modification’ Made by an unnamed employee at 3.15am. (TechCrunch)+ The topic is one the far-right comes back to again and again. (The Atlantic $)+ Memphis residents are struggling to live alongside xAI’s supercomputer. (CNBC) 2 Meta has delayed the launch of its next flagship AI model Its engineers are struggling to improve its Behemoth LLM enough. (WSJ $)3 Elon Musk is tapping up friends and allies for federal jobs It’s creating an unprecedented web of potential conflicts of interests. (WSJ $)+ Musk is posting on X less than he used to. (Semafor)4 The US is slashing funding for scientific research Such projects produced GPS, LASIK eye surgery, and CAPTCHAs. (NYT $)+ US tech visa applicants are under seriously heavy scrutiny. (Wired $)+ The foundations of America’s prosperity are being dismantled. (MIT Technology Review)They’re focusing on improving chatbots’ memory—but critics are worried. (5 Big Tech wants its AI agents to remember everything about you 🧠FT $)+ AI agents can spontaneously develop human-like behavior. (The Guardian)+ Generative AI can turn your most precious memories into photos that never existed. (MIT Technology Review)6 People keep making anti-DEI modifications for The Sims 4 And the gamemaker EA’s attempts to stamp them out aren’t working. (Wired $) 7 This chatbot promises to help you get over your ex  Closure creates an AI version of ex-partners for users to vent their frustrations at. (404 Media)+ The AI relationship revolution is already here. (MIT Technology Review)8 How this AI song became a viral megahit in JapanYAJU&U is completely inescapable, and totally nonsensical. (Pitchfork) + AI is coming for music, too. (MIT Technology Review) 9 Your future overseas trip could be by zeppelin If these startups get their way. (WP $)+ Welcome to the big blimp boom. (MIT Technology Review)10 Are you a ‘dry texter’? 💬 It’s a conflict-averse teen’s worst nightmare. (Vox) Quote of the day “It’s OK to be Chinese overseas.” —Chris Pereira, the CEO of iMpact, a communications firm advising Chinese companies expanding abroad, tells Rest of World that DeepSeek has given Chinese startups the confidence not to hide their origins. One more thingWe’ve never understood how hunger works. That might be about to change. When you’re starving, hunger is like a demon. It awakens the most ancient and primitive parts of the brain, then commandeers other neural machinery to do its bidding until it gets what it wants. Although scientists have had some success in stimulating hunger in mice, we still don’t really understand how the impulse to eat works. Now, some experts are following known parts of the neural hunger circuits into uncharted parts of the brain to try and find out. Their work could shed new light on the factors that have caused the number of overweight adults worldwide to skyrocket in recent years. And it could also help solve the mysteries around how and why a new class of weight-loss drugs seems to work so well. Read the full story. —Adam Piore We can still have nice things A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line or skeet 'em at me.)+ Who knew—Harvard Law School’s Magna Carta may be the real deal after all.+ Early relatives of reptiles might have walked the Earth much earlier than we realised.+ New York University’s MFA Students are a talented bunch.+ The Raines sandwich sounds unspeakably awful 🥪

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. This baby boy was treated with the first personalized gene-editing drug Doctors say they constructed a bespoke gene-editing treatment in less than seven months and used it to treat a baby with a deadly metabolic condition. The rapid-fire attempt to rewrite the child’s DNA marks the first time gene editing has been tailored to treat a single individual.The baby who was treated, Kyle “KJ” Muldoon Jr., suffers from a rare metabolic condition caused by a particularly unusual gene misspelling. Researchers say their attempt to correct the error demonstrates the high level of precision new types of gene editors offer. The project also highlights what some experts are calling a growing crisis in gene-editing technology. That’s because even though the technology could cure thousands of genetic conditions, most are so rare that companies could never recoup the costs of developing a treatment for them. Read the full story.—Antonio Regalado Access to experimental medical treatments is expanding across the US —Jessica Hamzelou A couple of weeks ago I was in Washington, DC, for a gathering of scientists, policymakers, and longevity enthusiasts. They had come together to discuss ways to speed along the development of drugs and other treatments that might extend the human lifespan. One approach that came up was to simply make experimental drugs more easily accessible. Now, the state of Montana has passed a new bill that sets out exactly how clinics can sell experimental, unproven treatments in the state to anyone who wants them. The passing of the bill could make Montana something of a US hub for experimental treatments. But it represents a wider trend: the creep of Right to Try across the US. And a potentially dangerous departure from evidence-based medicine. Read the full story. This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here. Take a new look at AI’s energy use Big Tech’s appetite for energy is growing rapidly as adoption of AI accelerates. But just how much energy does even a single AI query use? And what does it mean for the climate?Join editor in chief Mat Honan, senior climate reporter Casey Crownhart, and AI reporter James O’Donnell at 1.30pm ET on Wednesday May 21 for a subscriber-only Roundtables conversation exploring AI’s energy demands now and in the future. Register here. The must-reads I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology. 1 xAI has blamed Grok’s white genocide fixation on an ‘unauthorized modification’Made by an unnamed employee at 3.15am. (TechCrunch)+ The topic is one the far-right comes back to again and again. (The Atlantic $)+ Memphis residents are struggling to live alongside xAI’s supercomputer. (CNBC) 2 Meta has delayed the launch of its next flagship AI modelIts engineers are struggling to improve its Behemoth LLM enough. (WSJ $)  3 Elon Musk is tapping up friends and allies for federal jobsIt’s creating an unprecedented web of potential conflicts of interests. (WSJ $)+ Musk is posting on X less than he used to. (Semafor) 4 The US is slashing funding for scientific researchSuch projects produced GPS, LASIK eye surgery, and CAPTCHAs. (NYT $)+ US tech visa applicants are under seriously heavy scrutiny. (Wired $)+ The foundations of America’s prosperity are being dismantled. (MIT Technology Review)5 Big Tech wants its AI agents to remember everything about you They’re focusing on improving chatbots’ memory—but critics are worried. (FT $)+ AI agents can spontaneously develop human-like behavior. (The Guardian)+ Generative AI can turn your most precious memories into photos that never existed. (MIT Technology Review) 6 People keep making anti-DEI modifications for The Sims 4And the gamemaker EA’s attempts to stamp them out aren’t working. (Wired $) 7 This chatbot promises to help you get over your ex Closure creates an AI version of ex-partners for users to vent their frustrations at. (404 Media)+ The AI relationship revolution is already here. (MIT Technology Review) 8 How this AI song became a viral megahit in JapanYAJU&U is completely inescapable, and totally nonsensical. (Pitchfork)+ AI is coming for music, too. (MIT Technology Review) 9 Your future overseas trip could be by zeppelinIf these startups get their way. (WP $)+ Welcome to the big blimp boom. (MIT Technology Review) 10 Are you a ‘dry texter’? It’s a conflict-averse teen’s worst nightmare. (Vox) Quote of the day “It’s OK to be Chinese overseas.” —Chris Pereira, the CEO of iMpact, a communications firm advising Chinese companies expanding abroad, tells Rest of World that DeepSeek has given Chinese startups the confidence not to hide their origins. One more thingWe’ve never understood how hunger works. That might be about to change. When you’re starving, hunger is like a demon. It awakens the most ancient and primitive parts of the brain, then commandeers other neural machinery to do its bidding until it gets what it wants. Although scientists have had some success in stimulating hunger in mice, we still don’t really understand how the impulse to eat works. Now, some experts are following known parts of the neural hunger circuits into uncharted parts of the brain to try and find out. Their work could shed new light on the factors that have caused the number of overweight adults worldwide to skyrocket in recent years. And it could also help solve the mysteries around how and why a new class of weight-loss drugs seems to work so well. Read the full story. —Adam Piore We can still have nice things A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line or skeet ’em at me.)+ Who knew—Harvard Law School’s Magna Carta may be the real deal after all.+ Early relatives of reptiles might have walked the Earth much earlier than we realised.+ New York University’s MFA Students are a talented bunch.+ The Raines sandwich sounds unspeakably awful

A couple of weeks ago I was in Washington, DC, for a gathering of scientists, policymakers, and longevity enthusiasts. They had come together to discuss ways to speed along the development of drugs and other treatments that might extend the human lifespan. One approach that came up was to simply make experimental drugs more easily accessible. Let people try drugs that might help them live longer, the argument went. Some groups have been pushing bills to do just that in Montana, a state whose constitution explicitly values personal liberty. A couple of years ago, a longevity lobbying group helped develop a bill that expanded on the state’s existing Right to Try law, which allowed seriously ill people to apply for access to experimental drugs (that is, drugs that have not been approved by drug regulators). The expansion, which was passed in 2023, opened access for people who are not seriously ill.  Over the last few months, the group has been pushing further—for a new bill that sets out exactly how clinics can sell experimental, unproven treatments in the state to anyone who wants them. At the end of the second day of the event, the man next to me looked at his phone. “It just passed,” he told me. (The lobbying group has since announced that the state's governor Greg Gianforte has signed the bill into law, but when I called his office, Gianforte's staff told me they could not legally tell me whether or not he has.) The passing of the bill could make Montana something of a US hub for experimental treatments. But it represents a wider trend: the creep of Right to Try across the US. And a potentially dangerous departure from evidence-based medicine. In the US, drugs must be tested in human volunteers before they can be approved and sold. Early-stage clinical trials are small and check for safety. Later trials test both the safety and efficacy of a new drug. The system is designed to keep people safe and to prevent manufacturers from selling ineffective or dangerous products. It’s meant to protect us from snake oil. But people who are seriously ill and who have exhausted all other treatment options are often desperate to try experimental drugs. They might see it as a last hope. Sometimes they can volunteer for clinical trials, but time, distance, and eligibility can rule out that option. Since the 1980s, seriously or terminally ill people who cannot take part in a trial for some reason can apply for access to experimental treatments through a “compassionate use” program run by the US Food and Drug Administration (FDA). The FDA authorizes almost all of the compassionate use requests it receives (although manufacturers don’t always agree to provide their drug for various reasons). But that wasn’t enough for the Goldwater Institute, a libertarian organization that in 2014 drafted a model Right to Try law for people who are terminally ill. Versions of this draft have since been passed into law in 41 US states, and the US has had a federal Right to Try law since 2018. These laws generally allow people who are seriously ill to apply for access to drugs that have only been through the very first stages of clinical trials, provided they give informed consent. Some have argued that these laws have been driven by a dislike of both drug regulation and the FDA. After all, they are designed to achieve the same result as the compassionate use program. The only difference is that they bypass the FDA. Either way, it’s worth noting just how early-stage these treatments are. A drug that has been through phase I trials might have been tested in just 20 healthy people. Yes, these trials are designed to test the safety of a drug, but they are never conclusive. At that point in a drug’s development, no one can know how a sick person—who is likely to be taking other medicines— will react to it. Now these Right to Try laws are being expanded even more. The Montana bill, which goes the furthest, will enable people who are not seriously ill to access unproven treatments, and other states have been making moves in the same direction. Just this week, Georgia’s governor signed into law the Hope for Georgia Patients Act, which allows people with life-threatening illnesses to access personalized treatments, those that are “unique to and produced exclusively for an individual patient based on his or her own genetic profile.” Similar laws, known as “Right to Try 2.0,”  have been passed in other states, too, including Arizona, Mississippi, and North Carolina. And last year, Utah passed a law that allows health care providers (including chiropractors, podiatrists, midwives, and naturopaths) to deliver unapproved placental stem cell therapies. These treatments involve cells collected from placentas, which are thought to hold promise for tissue regeneration. But they haven’t been through human trials. They can cost tens of thousands of dollars, and their effects are unknown. Utah’s law was described as a “pretty blatant broadbrush challenge to the FDA’s authority” by an attorney who specializes in FDA law. And it’s one that could put patients at risk. Laws like these spark a lot of very sensitive debates. Some argue that it’s a question of medical autonomy, and that people should have the right to choose what they put in their own bodies. And many argue there’s a cost-benefit calculation to be made. A seriously ill person potentially has more to gain and less to lose from trying an experimental drug, compared to someone who is in good health. But everyone needs to be protected from ineffective drugs. Most ethicists think it’s unethical to sell a treatment when you have no idea if it will work, and that argument has been supported by numerous US court decisions over the years.  There could be a financial incentive for doctors to recommend an experimental drug, especially when they are granted protections by law. (Right to Try laws tend to protect prescribing doctors from disciplinary action and litigation should something go wrong.) On top of all this, many ethicists are also concerned that the FDA’s drug approval process itself has been on a downward slide over the last decade or so. An increasing number of drug approvals are fast-tracked based on weak evidence, they argue. Scientists and ethicists on both sides of the debate are now waiting to see what unfolds under the new US administration.   In the meantime, a quote from Diana Zuckerman, president of the nonprofit National Center for Health Research, comes to mind: “Sometimes hope helps people do better,” she told me a couple of years ago. “But in medicine, isn’t it better to have hope based on evidence rather than hope based on hype?” This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

A couple of weeks ago I was in Washington, DC, for a gathering of scientists, policymakers, and longevity enthusiasts. They had come together to discuss ways to speed along the development of drugs and other treatments that might extend the human lifespan. One approach that came up was to simply make experimental drugs more easily accessible. Let people try drugs that might help them live longer, the argument went. Some groups have been pushing bills to do just that in Montana, a state whose constitution explicitly values personal liberty. A couple of years ago, a longevity lobbying group helped develop a bill that expanded on the state’s existing Right to Try law, which allowed seriously ill people to apply for access to experimental drugs (that is, drugs that have not been approved by drug regulators). The expansion, which was passed in 2023, opened access for people who are not seriously ill.  Over the last few months, the group has been pushing further—for a new bill that sets out exactly how clinics can sell experimental, unproven treatments in the state to anyone who wants them. At the end of the second day of the event, the man next to me looked at his phone. “It just passed,” he told me. (The lobbying group has since announced that the state's governor Greg Gianforte has signed the bill into law, but when I called his office, Gianforte's staff told me they could not legally tell me whether or not he has.) The passing of the bill could make Montana something of a US hub for experimental treatments. But it represents a wider trend: the creep of Right to Try across the US. And a potentially dangerous departure from evidence-based medicine. In the US, drugs must be tested in human volunteers before they can be approved and sold. Early-stage clinical trials are small and check for safety. Later trials test both the safety and efficacy of a new drug. The system is designed to keep people safe and to prevent manufacturers from selling ineffective or dangerous products. It’s meant to protect us from snake oil. But people who are seriously ill and who have exhausted all other treatment options are often desperate to try experimental drugs. They might see it as a last hope. Sometimes they can volunteer for clinical trials, but time, distance, and eligibility can rule out that option. Since the 1980s, seriously or terminally ill people who cannot take part in a trial for some reason can apply for access to experimental treatments through a “compassionate use” program run by the US Food and Drug Administration (FDA). The FDA authorizes almost all of the compassionate use requests it receives (although manufacturers don’t always agree to provide their drug for various reasons). But that wasn’t enough for the Goldwater Institute, a libertarian organization that in 2014 drafted a model Right to Try law for people who are terminally ill. Versions of this draft have since been passed into law in 41 US states, and the US has had a federal Right to Try law since 2018. These laws generally allow people who are seriously ill to apply for access to drugs that have only been through the very first stages of clinical trials, provided they give informed consent. Some have argued that these laws have been driven by a dislike of both drug regulation and the FDA. After all, they are designed to achieve the same result as the compassionate use program. The only difference is that they bypass the FDA. Either way, it’s worth noting just how early-stage these treatments are. A drug that has been through phase I trials might have been tested in just 20 healthy people. Yes, these trials are designed to test the safety of a drug, but they are never conclusive. At that point in a drug’s development, no one can know how a sick person—who is likely to be taking other medicines— will react to it. Now these Right to Try laws are being expanded even more. The Montana bill, which goes the furthest, will enable people who are not seriously ill to access unproven treatments, and other states have been making moves in the same direction. Just this week, Georgia’s governor signed into law the Hope for Georgia Patients Act, which allows people with life-threatening illnesses to access personalized treatments, those that are “unique to and produced exclusively for an individual patient based on his or her own genetic profile.” Similar laws, known as “Right to Try 2.0,”  have been passed in other states, too, including Arizona, Mississippi, and North Carolina. And last year, Utah passed a law that allows health care providers (including chiropractors, podiatrists, midwives, and naturopaths) to deliver unapproved placental stem cell therapies. These treatments involve cells collected from placentas, which are thought to hold promise for tissue regeneration. But they haven’t been through human trials. They can cost tens of thousands of dollars, and their effects are unknown. Utah’s law was described as a “pretty blatant broadbrush challenge to the FDA’s authority” by an attorney who specializes in FDA law. And it’s one that could put patients at risk. Laws like these spark a lot of very sensitive debates. Some argue that it’s a question of medical autonomy, and that people should have the right to choose what they put in their own bodies. And many argue there’s a cost-benefit calculation to be made. A seriously ill person potentially has more to gain and less to lose from trying an experimental drug, compared to someone who is in good health. But everyone needs to be protected from ineffective drugs. Most ethicists think it’s unethical to sell a treatment when you have no idea if it will work, and that argument has been supported by numerous US court decisions over the years.  There could be a financial incentive for doctors to recommend an experimental drug, especially when they are granted protections by law. (Right to Try laws tend to protect prescribing doctors from disciplinary action and litigation should something go wrong.) On top of all this, many ethicists are also concerned that the FDA’s drug approval process itself has been on a downward slide over the last decade or so. An increasing number of drug approvals are fast-tracked based on weak evidence, they argue. Scientists and ethicists on both sides of the debate are now waiting to see what unfolds under the new US administration.   In the meantime, a quote from Diana Zuckerman, president of the nonprofit National Center for Health Research, comes to mind: “Sometimes hope helps people do better,” she told me a couple of years ago. “But in medicine, isn’t it better to have hope based on evidence rather than hope based on hype?” This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

A couple of weeks ago I was in Washington, DC, for a gathering of scientists, policymakers, and longevity enthusiasts. They had come together to discuss ways to speed along the development of drugs and other treatments that might extend the human lifespan. One approach that came up was to simply make experimental drugs more easily accessible. Let people try drugs that might help them live longer, the argument went. Some groups have been pushing bills to do just that in Montana, a state whose constitution explicitly values personal liberty. A couple of years ago, a longevity lobbying group helped develop a bill that expanded on the state’s existing Right to Try law, which allowed seriously ill people to apply for access to experimental drugs (that is, drugs that have not been approved by drug regulators). The expansion, which was passed in 2023, opened access for people who are not seriously ill.  Over the last few months, the group has been pushing further—for a new bill that sets out exactly how clinics can sell experimental, unproven treatments in the state to anyone who wants them. At the end of the second day of the event, the man next to me looked at his phone. “It just passed,” he told me. (The lobbying group has since announced that the state’s governor Greg Gianforte has signed the bill into law, but when I called his office, Gianforte’s staff told me they could not legally tell me whether or not he has.) The passing of the bill could make Montana something of a US hub for experimental treatments. But it represents a wider trend: the creep of Right to Try across the US. And a potentially dangerous departure from evidence-based medicine. In the US, drugs must be tested in human volunteers before they can be approved and sold. Early-stage clinical trials are small and check for safety. Later trials test both the safety and efficacy of a new drug. The system is designed to keep people safe and to prevent manufacturers from selling ineffective or dangerous products. It’s meant to protect us from snake oil. But people who are seriously ill and who have exhausted all other treatment options are often desperate to try experimental drugs. They might see it as a last hope. Sometimes they can volunteer for clinical trials, but time, distance, and eligibility can rule out that option. Since the 1980s, seriously or terminally ill people who cannot take part in a trial for some reason can apply for access to experimental treatments through a “compassionate use” program run by the US Food and Drug Administration (FDA). The FDA authorizes almost all of the compassionate use requests it receives (although manufacturers don’t always agree to provide their drug for various reasons). But that wasn’t enough for the Goldwater Institute, a libertarian organization that in 2014 drafted a model Right to Try law for people who are terminally ill. Versions of this draft have since been passed into law in 41 US states, and the US has had a federal Right to Try law since 2018. These laws generally allow people who are seriously ill to apply for access to drugs that have only been through the very first stages of clinical trials, provided they give informed consent. Some have argued that these laws have been driven by a dislike of both drug regulation and the FDA. After all, they are designed to achieve the same result as the compassionate use program. The only difference is that they bypass the FDA. Either way, it’s worth noting just how early-stage these treatments are. A drug that has been through phase I trials might have been tested in just 20 healthy people. Yes, these trials are designed to test the safety of a drug, but they are never conclusive. At that point in a drug’s development, no one can know how a sick person—who is likely to be taking other medicines— will react to it. Now these Right to Try laws are being expanded even more. The Montana bill, which goes the furthest, will enable people who are not seriously ill to access unproven treatments, and other states have been making moves in the same direction. Just this week, Georgia’s governor signed into law the Hope for Georgia Patients Act, which allows people with life-threatening illnesses to access personalized treatments, those that are “unique to and produced exclusively for an individual patient based on his or her own genetic profile.” Similar laws, known as “Right to Try 2.0,”  have been passed in other states, too, including Arizona, Mississippi, and North Carolina. And last year, Utah passed a law that allows health care providers (including chiropractors, podiatrists, midwives, and naturopaths) to deliver unapproved placental stem cell therapies. These treatments involve cells collected from placentas, which are thought to hold promise for tissue regeneration. But they haven’t been through human trials. They can cost tens of thousands of dollars, and their effects are unknown. Utah’s law was described as a “pretty blatant broadbrush challenge to the FDA’s authority” by an attorney who specializes in FDA law. And it’s one that could put patients at risk. Laws like these spark a lot of very sensitive debates. Some argue that it’s a question of medical autonomy, and that people should have the right to choose what they put in their own bodies. And many argue there’s a cost-benefit calculation to be made. A seriously ill person potentially has more to gain and less to lose from trying an experimental drug, compared to someone who is in good health. But everyone needs to be protected from ineffective drugs. Most ethicists think it’s unethical to sell a treatment when you have no idea if it will work, and that argument has been supported by numerous US court decisions over the years.  There could be a financial incentive for doctors to recommend an experimental drug, especially when they are granted protections by law. (Right to Try laws tend to protect prescribing doctors from disciplinary action and litigation should something go wrong.) On top of all this, many ethicists are also concerned that the FDA’s drug approval process itself has been on a downward slide over the last decade or so. An increasing number of drug approvals are fast-tracked based on weak evidence, they argue. Scientists and ethicists on both sides of the debate are now waiting to see what unfolds under the new US administration.   In the meantime, a quote from Diana Zuckerman, president of the nonprofit National Center for Health Research, comes to mind: “Sometimes hope helps people do better,” she told me a couple of years ago. “But in medicine, isn’t it better to have hope based on evidence rather than hope based on hype?” This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

It’s safe to say I’ve written about probably hundreds of EDC knives at this point – but hardly ever (if not never) written about an EDC sharpener. I’m not entirely sure if it’s even a category, but it is now, with the TiSpinx – a portable pendant-shaped knife sharpener that’s also a fidget spinner, and made almost entirely from titanium. Designed as jewelry, but functionally essential, the TiSpinx lets you keep your blades sharp no matter where you are. Three micro sharpening stones sit on the cylindrical surface of the TiSpinx, giving you a place to quickly (and effectively) jazz up any dull EDC blade you’ve got while outdoors. When you’re not whetting blades, the TiSpinx transforms into a fidget spinner, keeping your hands and mind occupied. All this sits in something the size of a piece of candy, making it perfectly portable, and ideal for stringing around a paracord, a keychain, a bracelet, or even a neck-chain. Designer: TIGO Click Here to Buy Now: $59 $89 (34% off) Hurry! Only 43 of 100 left. “The idea for TiSpinx was born from a common outdoor frustration. On a camping trip, a dull knife became a real problem—and sharpening it with rough stones just didn’t cut it,” said the folks at TIGO, who designed the TiSpinx. You see, EDC knives are a dime a dozen, and a decent amount of them are designed to stay sharp for years. But that promise is only good up until you’re faced with a dull blade that doesn’t slice through wood or cut paracord. That’s when the TiSpinx comes in handy, giving you a proper place to sharpen your blade rather than a random rock on a riverbank. But wearing a knife sharpener around your neck isn’t particularly glamorous – which is why TIGO took a subtle, yet sophisticated approach to making the TiSpinx. It had to be a sharpener, but it had to be more than just one too. The result, a pendant-shaped bead-like EDC that also doubled as a fidget spinner. With 3 micro sharpening stones, 9 tritium slots, and a hollow, compact design, the TiSpinx easily fits on bracelets, keyrings, or necklaces. It has the appeal of a dog tag, while being functional too. Spin it when you’re bored, sharpen knives when you’re equipped with dull blades, and show it off as haute outdoor jewelry when you’re just going about your day. The entire device is machined from GR5 titanium, a bona fide EDC-grade metal known for its lightweight, rugged nature. The TiSpinx measures under an inch high and wide (a 25.3mm x 19.9mm cylinder to be precise), and weighs a paltry 19.2 grams or 0.6 ounces. That officially makes it the smallest knife sharpener ever made, and the only one designed to be worn as EDC jewelry. The titanium construction houses 3 tiny sharpening stones that can easily be removed and flipped over if they get dirty. Meanwhile, an integrated ball-bearing system allows the TiSpinx to double as a silent fidget spinner. The tiny whetstones are made from Alumina or aluminum oxide – a hard, amorphous material extracted from bauxite ore. It’s known for its hardness and abrasion resistance, making it perfect for sharpening all kinds of blades, even ones made from tough high-chromium steel. Three strategically placed stones on the TiSpinx give you three surfaces to sharpen your blade on. You can choose to wet the stone too, for a cleaner experience – titanium is naturally rust-proof, making it the perfect material for the TiSpinx. The TiSpinx comes in 3 colors – a plain, sandblasted finish for lovers of the classic titanium color, an anodized yellow for people who want their sharpener/pendant to also have a little bling, and a PVD black for lovers of stealth. Each TiSpinx also comes with a total of 9 tritium slots, which you can put glow-vials into, giving the pendant a unique appeal while also allowing it to be visible in the dark. The TiSpinx starts at a discounted $59, which feels like a steal given most knives often cost the same amount, and this product basically extends the lifespan of every one of those knives. It’s jewelry, it’s EDC, it’s a fidget toy, but it’s also an investment in the longevity of your favorite blades, which is a laundry list of features that no other product I’ve ever written about has. I mean, a wearable knife sharpener that also happens to be a fidget pendant? And comes with a titanium construction that’s guaranteed to last a lifetime? It’s practically a dream for EDC enthusiasts, outdoor lovers, knife nerds, and just about anyone who adores functional jewelry. Click Here to Buy Now: $59 $89 (34% off) Hurry! Only 43 of 100 left.The post World’s Smallest Knife Sharpener Doubles as a Titanium EDC Pendant You Can Wear first appeared on Yanko Design.

A cat with seasonal allergies tries to scratch his ear.getty Minnesota resident Mary Tan travels frequently with her outgoing “adventure cat,” Franklin, a rescued orange tabby. But a couple of years ago when she was traveling solo and her sister was pet sitting for her, she received a phone call that changed daily life. “My sister called me and said, ‘I think Franklin has ear mites.’ And I’m like, ‘What? There's no way,'” she said. “I was freaking out.” As soon as Tan got home, she rushed her cat to the veterinarian, who determined Franklin didn’t have ear mites: he had severe allergies. The “black crud” in the cat’s ears turned out to be bacteria and yeast. Tan, a longtime animal foster, adopter and founder of Whisker Media, learned through testing that Franklin is allergic to just about everything outdoors — particularly pollen and grass. Though he’s an indoor cat, he does take leashed walks in the neighborhood with Tan and travels to tradeshows as a brand ambassador and to a nursing home to offer comfort to residents. After about six months of trial-and-error treatments with different medications and dosages, Franklin’s veterinarian referred him to a board-certified veterinary dermatologist. He’s much better, but he doesn’t take leashed walks in the springtime when pollen levels are high, and his condition will need to be carefully managed for the rest of his life.Franklin Delano Tan, who is named after Franklin Delano Roosevelt “because you have to negotiate ... More with him,” suffers from severe seasonal allergies that affect his skin and ears, according to Mary Tan.Mary Tan Tan is committed to doing whatever it takes to help her cat with his severe seasonal allergies because it was “distressing” to see him so uncomfortable and itchy, often scratching his ears until they turned red. “I had to do something. My pets are my children,” she said. “I’ve never encountered anything like this.” A Veterinarian’s Perspective On Seasonal Allergies In Cats Cats can have mild to severe symptoms from season allergies — just like humans, according to Gary Richter, DVM, owner of Holistic Veterinary Care and Rehabilitation Center in Oakland, California and author of The Ultimate Pet Health Guide. “With cats, it's either skin or it can also be respiratory,” he said. “Just like with people, cats can be very sensitive in their respiratory tracts. So coughing, wheezing, even asthma, things of that nature.” Cats can react to the common allergens that affect humans, such as pollen, mold and dust, he noted. When allergies affect feline skin, symptoms include scratching at their face and ears, scabs on their skin and fur loss. “Cats being cats, they do a lot of grooming,” he said. “So sometimes what will happen is cats will start overgrooming and licking off fur. It can manifest in any number of ways."Cats fastidiously groom themselves, but they can overdo it when they are itchy from seasonal ... More allergies.getty Prevention Tips For Seasonal Allergies Dr. Richter’s top tip for helping cats with seasonal allergies — and to boost their overall health and longevity — is to keep them indoors. “Statistically speaking, cats live dramatically longer if they’re indoors than if they’re going outside,” he said. “It’s safer for the cat, it’s safer for the environment because cats are sort of relentless predators, so they’re always hunting things like birds and other small animals. It’s not impossible for a cat to have seasonal allergies indoors, but clearly their exposure is going to be dramatically lower if they’re not outside in the grass.” Indoor cats can also benefit from homes that run the air conditioner instead of opening windows. Dr. Richter recommends regularly changing or cleaning the filters in the air conditioner and possibly investing in a HEPA air purifier to help decrease exposure to dust and pollen. Additionally, he feels good nutrition can bolster a cat’s immune system. His preference is to feed pets whole foods, though he noted people concerned about bird flu in cats should avoid feeing them raw poultry. Treatment Options For Cats With Seasonal AllergiesKittens and cats can develop seasonal allergies to common allergens like grass and pollen.getty Treatment options run for cats with seasonal allergies run the gamut depending on the severity of symptoms, according to Dr. Richter. On the mild end of the spectrum, he suggests trying fish oil supplements and natural anti-inflammatories and antioxidants, such as quercetin and astaxanthin and herbal extracts like nettle extract. (Dr. Richter formulated a combination product called Feline Renew with omega fats and antioxidants.) Zimox, an over-the-counter enzymatic product, can help with some skin and ear infections without the potential side effects of pharmaceutical antibiotics and antifungals, he noted. “My preference as an integrative and holistic doctor is always to try and avoid the really strong immunomodulating immunosuppressive pharmaceuticals if we can get away with it,” he said. But if natural approaches don’t work, he “absolutely” recommends calling your veterinarian. Treatment for more serious allergies includes oral and injectable medications and medicated shampoos. Seeking Help For Seasonal Allergies Based on personal experience, Rachel Geller, Ed.D., founder of the nonprofit All Cats All the Time, recommends calling your veterinarian as soon as you notice any unusual symptoms in cats. Several years ago, she was concerned when her rescue cat, Sosil (a Yiddish word for “sweet"), appeared to have scabs on her face. She initially assumed the Maine Coon mix had tussled with one of her other cats. But when Sosil didn’t seem to be getting better, veterinary testing revealed she didn’t have a skin infection or cancer, but allergies.Sosil experiences severe seasonal allergies marked by itchy skin and lesions. “It’ll be raw, it’ll ... More be a little bloody, the fur will be gone,” says Dr. Rachel Geller. “You can see her skin, but the skin will be red and raw.”Dr. Rachel Geller Prescription food for cats with sensitive skin and stomachs kept symptoms at bay for a couple of years, but one dry winter, “these allergies reared their ugly head again,” according to Dr. Geller. “She will get these skin allergies and it can range from some raw lesions on her face to really bad lesions around her mouth and nose and even on her gums,” she said. “It can very easily become infected, which has happened before. Then it spreads.” During allergy flares, Sosil rubs her face on table corners to try to scratch the itchiness. So now at the first sign of any redness or rawness, Dr. Geller takes her cat straight to the animal hospital for a shot of steroids and the antibiotic injection Convenia. Sosil suffered abuse in her former home and mistrusted people when Dr. Geller adopted her six years ago, but she’s transformed into “the sweetest, wonderful cat" who is now part of the family. So Dr. Geller does whatever she can to help the 12-year-old cat — just as she would for any beloved family member. “She’s worth every penny,” she said. “I would do anything for this little baby to keep her healthy and happy. That’s what we sign up for.”

Some decorating trends will come and go (see millennial pink) while others have longevity, no matter what era we're in. One such aesthetic? Tasteful horse decor. Between Netflix's recent hit Ransom Canyon, the U.S. Polo championships back in April, and the many home tours we've published featuring horse motifs, everyone, including the design world, is enthralled with these creatures right now. While luxury fashion brands such as Ralph Lauren and Hermès may have introduced equestrian vibes into interiors (horses being an instantly recognizable part of both brands' identities), the look has evolved beyond just their ateliers. "Horses have always been a popular subject in the art and design world, going back to early cave drawings in the Lascaux Cave, France. It is so fun to see them back in the spotlight in interiors," designer Maria Burke says. "We have definitely seen a resurgence in layered, British interior style, so I think it is fitting that all sorts of equestrian subjects and patterns have also seen a rise in popularity." While several designers we spoke with mentioned the influence of British style in homes right now, others link our current fascination with the Wild West to a yearning for a different time. manufoto llcA horse sculpture nestled amongst candle holders is the perfect final decorative touch.Anson SmartMix and match art mediums, like textured pieces and a photo, in a room."Across the board, we're seeing a major shift back to traditional, cozy, old-world design. I think it's everyone's desire for comfort and reassurance during these rocky political and technological times. A return to our roots. It's the antithesis to AI," award-winning interior designer Lindsay Gerber Northart says. "The resurgence [of horse decor] seems to stem from a deep-seated yearning for connection with nature and a romanticized notion of freedom and open horizons," L.A.-based designer Jennifer Miller adds. "Horses embody both untamed beauty and a sense of serene strength in their powerful yet graceful presence. This inherent duality resonates with contemporary desires for authenticity and a touch of the organic within our living spaces." Indeed, in a world where we are scrolling endlessly on TikTok, checking our work emails while on vacation, or being spammed with fake phone calls daily, returning to a world that ran at a slower pace seems idyllic. Designers everywhere, from Los Angeles to Virginia, are seeing an uptick in client requests for incorporating horse decor into their homes. Burke notes that in one of her projects, they recently took the client's collection of riding crops and turned them into a gallery on their second-floor hallway. Meanwhile, Jeanne Barber, founder of Camden Grace Interiors, recalls a client in the New York City suburbs asking them to adorn her husband's office in oil paintings featuring hunts and horses. As you may be able to tell, if you love these majestic animals, there are plenty of ways to capture their essence in your home. "There's a romanticism to equestrian imagery that evokes both rustic countryside charm and old-world luxury, making it incredibly versatile across styles, from modern farmhouse to classic traditional and even minimalist spaces," designer Katie McCaffrey says. Tasteful horse decor is here to stay—forever—so check out the expert styling tips ahead on achieving the look seamlessly in your home. Related Story Make It Feel Modern Patrick BillerThe office is a great place to show off your love of the equestrian sport.Mixing new pieces with vintage finds is a tried-and-true furnishing method that gives your home its character. Even though this takes time, we're firm believers in slow decorating. When it comes to horse decor, Burke recommends employing the same method by merging "old master-style oil paintings with horse subjects above more modern pieces of furniture." If you already have such works of art, you're one step ahead of everyone else. However, if you're sourcing art from scratch, Burke says, "These works can easily be found on auction sites and even consignment stores if you are up for the challenge, and they make for a wonderful mix with newer pieces." We suggest checking out places like Chairish, 1stdibs, LiveAuctioneers, and Everything But the House.Related StoryLean Into Antique SculpturesJeanne BarberSculptures can be placed anywhere, including on a bar cart.Besides framed artwork, designers suggest adding horse sculptures to your space, whether that's a small statue of a stallion nestled on your bookshelf or a giant horse head that commands attention near your staircase. The best part about these pieces is that you can move them around the house anytime without having to deal with annoying photo hooks or adhesive strips. "In my own home, I have a large, cast-iron horse head that meanders through my house, depending on my mood," Barber says. "Lately, he's hanging out on our porch bar, greeting guests with a cocktail." Opt for Striking Photography© Rustic White Photography,LLCBuy a big print from your favorite photographer and hang it where everyone can admire it.Whether you dabble in photography or follow a National Geographic photographer who shoots the most amazing wildlife, if this is your art medium of choice, incorporating a stunning visual of a horse in your space is a no-brainer. "Professional equine photographers are increasingly producing some spectacular large-format images in both black and white and color. These can be striking statements alone or as a collection, and really set a sophisticated, luxurious vibe to any space," says designer and passionate equestrian Megan Winters. Don't Be ObviousAlanna HalePlaid, iron, brass, and leather can help you tap into the look more subtly.Yes, you can display tasteful horse decor without horses! If you're not into the animalcore look, you can instead hint at your love for them through horse-adjacent decor. "I think horse decor needs to be more of a nod and hint rather than literal...otherwise you're very easily getting into a tacky decor situation," Gerber Northart says. "Introduce patinated old leather pieces and brass accent pieces, which hint at the look and feel of horse tack. Wool and plaids hint at a fox hunt." Similarly, McCaffrey suggests using "checks, plaids, natural materials such as woven baskets to evoke equestrian style without being too literal." Related StoryLittle Touches Go a Long Way Michael CliffordShow restraint when leaning into the equestrian theme.All the designers we spoke with agree on one thing when it comes to making your horse decor feel tasteful: moderation is key. "I like to try to limit the use of a 'themed' element to one or two items per room," Burke says. "Instead of layering all sorts of prints with an actual horse on it [throughout the home], we will use one and then draw inspiration from other sorts of horse-related items, such as leather, thick wool blankets, and dark iron [for the other spaces].""The key is to ensure the execution feels intentional and contributes to the overall narrative of the space," Miller adds. "In our Sun Valley project, we incorporated a few horse drawings and a red horse painting I created myself, which felt especially fitting for the setting and served as a nod to the Western heritage and natural beauty of the area. The artwork reflects the landscape’s rustic spirit while adding a personal layer of storytelling." Shop Our Favorite Horse Decor PicksHermès Cheval Deco Ashtray$800 at HermesGucci Velvet Cushion With Horsebit$1,150 at GucciCharles MARECHAL (1865-1931), Horses in landscape oil on canvas$300 at liveauctioneers.comCarol Walker Leopard Appaloosa - Limited Edition of 100 Photograph$1,830 at saatchiart.comRalph Lauren Home Dalton Accent Table$18,790 at Ralph LaurenWilliams Sonoma Cashmere & Wool Equestrian Throw$499 at Williams SonomaKathy Kuo Monty French Country Black Aged Metal Round Side End Table$141 at kathykuohome.comRalph Lauren Home Brennan Clock$1,195 at Ralph LaurenArt Deco Style Silvered Brass Etruscan Horse Sculpture$4,250 at 1stDibsJoon Loloi Morison Leather Wrapped Table Lamp$199 at joonloloi.comFollow House Beautiful on Instagram and TikTok.